Your browser doesn't support javascript.
loading
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Blum, Kristie A; Supko, Jeffrey G; Maris, Michael B; Flinn, Ian W; Goy, Andre; Younes, Anas; Bobba, Suresh; Senderowicz, Adrian M; Efuni, Sergey; Rippley, Ronda; Colak, Gozde; Trojer, Patrick; Abramson, Jeremy S.
Afiliación
  • Blum KA; Emory University School of Medicine, Atlanta, Georgia.
  • Supko JG; Massachusetts General Hospital, Boston, Massachusetts.
  • Maris MB; Colorado Blood Cancer Institute, Denver, Colorado.
  • Flinn IW; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, Tennessee.
  • Goy A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
  • Younes A; Memorial Sloan Kettering Cancer Center, New York City, New York.
  • Bobba S; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.
  • Senderowicz AM; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.
  • Efuni S; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.
  • Rippley R; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.
  • Colak G; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.
  • Trojer P; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.
  • Abramson JS; Massachusetts General Hospital, Boston, Massachusetts.
Cancer Res Commun ; 2(8): 795-805, 2022 08.
Article en En | MEDLINE | ID: mdl-36923307

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma / Antineoplásicos Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Georgia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma / Antineoplásicos Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Georgia